WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (the "Company") today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities...
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further...
– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12,...
In a report released today, Lachlan Hanbury Brown from William Blair maintained a Hold rating on Lyra Therapeutics. The company’s shares closed yesterday at $7.92.Elevate Your Investing Strategy: Take...
William Blair analyst Lachlan Hanbury Brown maintained a Hold rating on Lyra Therapeutics today. The company’s shares opened today at $7.47.Elevate Your Investing Strategy: Take advantage of TipRanks...
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct....
– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210...
U.S. stocks drifted higher and pulled closer to their record as the wait continues for more updates on President Donald Trump’s tariffs and how much they’re affecting the economy
U.S. stock indexes drifted closer to records, coming off their stellar May